BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...to two biosimilars for eye diseases, Lucentis ranibizumab...
BioCentury | Jan 29, 2021
Distillery Therapeutics

VEGF-A gene editing therapy to treat wet AMD

...63%.The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Novartis AG (NYSE:NVS; SIX:NOVN) market Lucentis ranibizumab...
...for DME.Samsung Bioepis Co. Ltd., AffaMed Therapeutics (Shanghai) Co. Ltd., Biogen Inc. (NASDAQ:BIIB) and Samsung Group have a biosimilar ranibizumab...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...2019 deal with Samsung Bioepis Co. Ltd., including rights in China to biosimilars to Lucentis ranibizumab...
BioCentury | Aug 29, 2020
Emerging Company Profile

Arctic Vision sets sights on China’s innovation gap in ophthalmology

...recently as medial director for Asia Pacific, Middle East and African Countries. There, he helped develop Lucentis ranibizumab...
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

...as infrequently as once yearly, Heah said. Dosing of retinal therapies Eylea aflibercept and Lucentis ranibizumab...
...and Bayer AG (Xetra:BAYN) share Eylea’s rights, while Novartis AG (NYSE:NVS; SIX:NOVN) and Roche market Lucentis...
...Eylea. Another company, Kodiak Sciences Inc. (NASDAQ:KOD), has late-stage candidate KSI-301, a mAb similar to Lucentis...
BioCentury | Dec 21, 2019
Product Development

China a priority for Novartis’ Narasimhan

...catch-up. So in the pharmaceutical segment, we already have a very sizable presence -- Entresto, Lucentis...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

...the other approach. Adverum’s lead product directly incorporates Eylea, and RegenxBio's is based on Lucentis ranibizumab--two...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...the JV's anti-TNF portfolio. Biogen will receive territorial rights to SB11, a biosimilar of Lucentis ranibizumab...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...494%. On August 4, the company reported its OPT-302 plus Lucentis ranibizumab was superior to Lucentis...
BioCentury | Sep 20, 2019
Company News

Xospata poised for EU approval under accelerated assessment

...an add-on to intranasal corticosteroids in adults with severe chronic rhinosinusitis with nasal polyposis; Lucentis ranibizumab...
...#), dupilumab (Generic), Dupixent (Informal) Lucentis (Brand), RG3645 (Compound #), rhuFab V2 (Former compound #), ranibizumab (Generic), Lucentis...
Items per page:
1 - 10 of 706